Starting Mirtazapine at 7.5 mg Before Increasing to 15 mg
No, the patient should start directly at 15 mg once daily rather than beginning at 7.5 mg, as the FDA-approved starting dose is 15 mg and lower doses may provide inadequate antidepressant effect while potentially causing more sedation. 1
FDA-Approved Dosing Recommendations
- The FDA label explicitly states that the recommended starting dose is 15 mg once daily, administered orally, preferably in the evening prior to sleep 1
- Dose changes should not be made in intervals of less than 1 to 2 weeks to allow sufficient time for evaluation of response to a given dose 1
- If patients do not have an adequate response to the initial 15 mg dose, the dose can be increased up to a maximum of 45 mg per day 1
Why 7.5 mg is Not Recommended for Depression Treatment
- The 7.5 mg dose is associated with MORE sedation, not less, due to mirtazapine's unique pharmacology 2, 3
- At subtherapeutic dosages below 15 mg, increased sedation is more commonly reported, and this sedation is substantially reduced when the drug is used in appropriate dosages (≥15 mg) from the beginning of treatment 2
- The 7.5 mg dose is primarily used off-label for insomnia, not for treating major depressive disorder 4
Monitoring Timeline After Starting Treatment
- The American College of Physicians recommends beginning to assess patient status, therapeutic response, and adverse effects within 1-2 weeks of treatment initiation 5
- If the patient does not have an adequate response within 6-8 weeks, treatment modification is strongly recommended 5
- Mirtazapine shows an early onset of action, with significant improvements noted as early as 1-2 weeks after starting treatment at therapeutic doses 6, 2
Common Pitfalls to Avoid
- Starting too low (7.5 mg) paradoxically causes more sedation due to predominant H1 receptor antagonism at lower doses, while higher therapeutic doses engage the noradrenergic mechanisms that counteract sedation 2, 3
- Waiting too long between dose adjustments—the FDA recommends evaluating response every 1-2 weeks, not waiting longer 1
- Failing to screen for bipolar disorder before initiating treatment, as required by FDA labeling 1